Challenge <p> Developing a Clinically Relevant Tenacibaculosis Challenge Model</p>

Developing a Clinically Relevant Tenacibaculosis Challenge Model

Award:  $100,000 USD
Deadline: Aug 15 2018 23:59 EDT
Active Solvers: 101
Posted: Aug 15 2017
Challenge ID: 9933920
Team Project Rooms are available on this Challenge. Team Share Challenge Share

The salmon farming industry has grown rapidly to meet consumer demand and consumption. Enclosing a large number of fish in close quarters increases the risk of outbreaks, so vaccine immunizations are used as preventative measures. However, efficacious vaccines are lacking for certain diseases, for example winter ulcers. Although Tenacibaculum species have been implicated in disease development, there is currently no animal model to support further research. Therefore, the Seeker desires an in vivo tenacibaculosis challenge model.

The Challenge has a special award structure. A solution proven to be viable for both warm and cold water temperatures will be eligible for multiple awards of $100,000 each.

This is a Reduction-to-Practice Challenge that requires written documentation and experimental proof-of-concept data (and/or sample delivery).


The use of vaccines for disease prevention in aquaculture has been well established. Moritella viscosa is the bacterial pathogen most commonly associated with winter ulcers in Atlantic salmon. Originally thought to be a disease restricted to cold temperatures, signs of winter ulcer disease have recently been observed in fish during the summer months. This non-classical presentation suggests that additional pathogens may be involved and strains of Tenacibaculum have been isolated from these lesions. In order to study the biology of Tenacibaculum infection and accelerate vaccine development, the Seeker desires an in vivo tenacibaculosis challenge model.

A submission to the Challenge should include the following:

  1. The detailed description of the proposed Solution addressing specific Solution Requirements presented in the Detailed Description of the Challenge. This should be accompanied by a well-articulated rationale supported by literature precedents.
  2. Experimental proof-of-concept data obtained as outlined in the Detailed Description of the Challenge (and/or delivery of a material sample if requested by the Seeker).
  3. The Seeker will determine which Solutions merit experimental validation. Solvers will be notified if and when to ship their isolate(s).  

The Challenge award is contingent upon theoretical evaluation and experimental validation of the submitted solutions by the Seeker.

To receive an award, the Solvers will have to transfer to the Seeker their exclusive intellectual property (IP) rights to the solution. However, the Seeker will be willing to consider a licensing agreement for a partial award if exclusive IP cannot be transferred by the Solver.

Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on August 15, 2018. 

Late submissions will not be considered.

What is InnoCentive?
InnoCentive is the global innovation marketplace where creative minds solve some of the world's most important problems for cash awards up to $1 million. Commercial, governmental and humanitarian organizations engage with InnoCentive to solve problems that can impact humankind in areas ranging from the environment to medical advancements.

What is an RTP Challenge?

An InnoCentive RTP (Reduction to Practice) Challenge is a prototype that proves an idea, and is similar to an InnoCentive Theoretical Challenge in its high level of detail. However, an RTP requires the Solver to submit a validated solution, either in the form of original data or a physical sample. Also the Seeker is allowed to test the proposed solution. For details about treatment of IP rights, please see the Challenge-Specific Agreement.

Share This Challenge
Challenge Data (What's This?)
Table showing data points for submissions recieved
Table showing data points for submissions recieved
Solver Map
Solver Map
InnoCentive Trust Partners